{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:42:48Z","timestamp":1785332568242,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,6]]},"DOI":"10.7759\/cureus.89514","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T03:54:53Z","timestamp":1754538893000},"source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes Mellitus With Atherosclerotic Cardiovascular Disease: A Systematic Review of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Maria","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Sikandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisam","family":"Bachar Al Sumodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Hans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia U","year":"2020","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S, et al.. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020, 21:6275. 10.3390\/ijms21176275","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002407","article-title":"Type 2 diabetes and the risk of cardiovascular events in peripheral artery disease versus coronary artery disease","volume":"9","author":"Sprenger L","year":"2021","unstructured":"Sprenger L, Mader A, Larcher B, et al.. Type 2 diabetes and the risk of cardiovascular events in peripheral artery disease versus coronary artery disease. BMJ Open Diabetes Res Care. 2021, 9:002407. 10.1136\/bmjdrc-2021-002407","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz A","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med. 2025, 138:934-40. 10.1016\/j.amjmed.2025.01.021","journal-title":"Am J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.125.074545","article-title":"Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the soul randomized trial","volume":"151","author":"Marx N","year":"2025","unstructured":"Marx N, Deanfield JE, Mann JF, et al.. Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the soul randomized trial. Circulation. 2025, 151:1639-50. 10.1161\/CIRCULATIONAHA.125.074545","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic V","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al.. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024, 391:109-21. 10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.04.038","article-title":"Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction: the step-HFpEF program","volume":"84","author":"Schou M","year":"2024","unstructured":"Schou M, Petrie MC, Borlaug BA, et al.. Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction: the step-HFpEF program. J Am Coll Cardiol. 2024, 84:247-57. 10.1016\/j.jacc.2024.04.038","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919893361","article-title":"A review of the PubMed Pico tool: using evidence-based practice in health education","volume":"21","author":"Brown D","year":"2020","unstructured":"Brown D. A review of the PubMed Pico tool: using evidence-based practice in health education. Health Promot Pract. 2020, 21:496-8. 10.1177\/1524839919893361","journal-title":"Health Promot Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire DK","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, et al.. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025, 392:2001-12. 10.1056\/NEJMoa2501006","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod MN","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, et al.. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024, 404:949-61. 10.1016\/S0140-6736(24)01643-X","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the flow trial","volume":"84","author":"Pratley RE","year":"2024","unstructured":"Pratley RE, Tuttle KR, Rossing P, et al.. Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the flow trial. J Am Coll Cardiol. 2024, 84:1615-28. 10.1016\/j.jacc.2024.08.004","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.04.022","article-title":"Semaglutide and NT-proBNP in obesity-related HFpEF: insights\u00a0from\u00a0the\u00a0STEP-HFpEF\u00a0program","volume":"84","author":"Petrie MC","year":"2024","unstructured":"Petrie MC, Borlaug BA, Butler J, et al.. Semaglutide and NT-proBNP in obesity-related HFpEF: insights\u00a0from\u00a0the\u00a0STEP-HFpEF\u00a0program. J Am Coll Cardiol. 2024, 84:27-40. 10.1016\/j.jacc.2024.04.022","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3478","article-title":"Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: the EXSCEL trial","volume":"27","author":"Neves JS","year":"2025","unstructured":"Neves JS, Leite AR, Mentz RJ, et al.. Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: the EXSCEL trial. Eur J Heart Fail. 2025, 27:540-51. 10.1002\/ejhf.3478","journal-title":"Eur J Heart Fail"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein HC","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al.. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019, 394:121-30. 10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann JF","year":"2024","unstructured":"Mann JF, Rossing P, Bakris G, et al.. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024, 30:2849-56. 10.1038\/s41591-024-03133-0","journal-title":"Nat Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma X","year":"2021","unstructured":"Ma X, Liu Z, Ilyas I, et al.. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021, 17:2050-68. 10.7150\/ijbs.59965","journal-title":"Int J Biol Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-023-02124-w","article-title":"GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?","volume":"60","author":"Menghini R","year":"2023","unstructured":"Menghini R, Casagrande V, Rizza S, Federici M. GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?. Acta Diabetol. 2023, 60:1441-8. 10.1007\/s00592-023-02124-w","journal-title":"Acta Diabetol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v15.i5.818","article-title":"Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: myth or truth?","volume":"15","author":"Nesti L","year":"2024","unstructured":"Nesti L, Trico D. Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: myth or truth?. World J Diabetes. 2024, 15:818-22. 10.4239\/wjd.v15.i5.818","journal-title":"World J Diabetes"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1966","article-title":"Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review","volume":"5","author":"Honigberg MC","year":"2020","unstructured":"Honigberg MC, Chang LS, McGuire DK, Plutzky J, Aroda VR, Vaduganathan M. Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review. JAMA Cardiol. 2020, 5:1182-90. 10.1001\/jamacardio.2020.1966","journal-title":"JAMA Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01722-x","article-title":"Combining GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes mellitus: a scoping review and expert insights for clinical practice utilizing the nominal group technique","volume":"16","author":"Yepes-Cort\u00e9s CA","year":"2025","unstructured":"Yepes-Cort\u00e9s CA, Cardenas-Moreno IC, Daza-Arnedo R, et al.. Combining GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes mellitus: a scoping review and expert insights for clinical practice utilizing the nominal group technique. Diabetes Ther. 2025, 16:813-49. 10.1007\/s13300-025-01722-x","journal-title":"Diabetes Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/393298-cardiovascular-benefits-of-glucagon-like-peptide-1-glp-1-receptor-agonists-in-type-2-diabetes-mellitus-with-atherosclerotic-cardiovascular-disease-a-systematic-review-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T03:54:56Z","timestamp":1754538896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/393298-cardiovascular-benefits-of-glucagon-like-peptide-1-glp-1-receptor-agonists-in-type-2-diabetes-mellitus-with-atherosclerotic-cardiovascular-disease-a-systematic-review-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.89514","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,6]]}}}